Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID‐19 patient with multimorbidity
Open Access
- 22 February 2021
- journal article
- research article
- Published by Wiley in Clinical Case Reports
- Vol. 9 (4), 2132-2137
- https://doi.org/10.1002/ccr3.3964
Abstract
Combination of convalescent plasma therapy and repurposed drugs such as dexamethasone and remdesivir could be beneficial for severe COVID‐19 patients with obesity and chronic diseases such as diabetes and hypertension.Keywords
This publication has 17 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Convalescent plasma treatment of severe COVID-19: a propensity score-matched control studyNature Medicine, 2020
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)BMJ, 2020
- WHO Coronavirus Disease (COVID-19) DashboardBangladesh Physiotherapy Journal, 2020
- Current Overview on Hypercoagulability in COVID-19American Journal of Cardiovascular Drugs, 2020
- Multisystem Inflammatory Syndrome in U.S. Children and AdolescentsNew England Journal of Medicine, 2020
- Clinical determinants for fatality of 44,672 patients with COVID-19Critical Care, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences of the United States of America, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJama-Journal Of The American Medical Association, 2020
- Covid-19: risk factors for severe disease and deathBMJ, 2020